olverembatinib
ascentage pharmaceuticals
['ascent', 'olverembatinib', 'ascentage pharma', 'ascentage']
asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential with a clinical benefit rate of 83.3% ascentage pharma announced that it has released the latest results from a phase ib/ii study of the 
All things biotech.